Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Characterisation of Immunological and Molecular Changes Evolving in Patients Undergoing Radiotherapy (CHIMERA) (CHIMERA)

9 november 2026 uppdaterad av: Royal Marsden NHS Foundation Trust

Radiotherapy is thought to trigger an immune response, and the particular type of immune response may depend on the biology of individual tumours. By studying changes in the immune response and tumour biology during and after radiotherapy, we will gain a better understanding of how different types of radiotherapy, and different tumour types, affect the immune response. This is important for optimising personalised radiotherapy treatment, including in combination with other immunotherapy agents. There is minimal published data reporting feasibility of the above approach, or to guide power calculations. This means pilot work is needed to establish both feasibility and proof-of principle.

The CHIMERA protocol is a non-interventional single site study involving sample collection (blood and tumour samples) from patients before, during and after radiotherapy. A maximum of four tumour research biopsies are further optional research samples. The primary and secondary objectives of the CHIMERA protocol are to establish feasibility of longitudinal characterisation of firstly the immune response, and secondly tumour biology before, during and after radiotherapy.

Any patient receiving radiotherapy at The Royal Marsden NHS Trust is eligible for CHIMERA provided they are able to provide informed consent, attend follow up appointments and do not have an immunosuppressive infection.

If feasibility criteria are met for profiling of the immune response and tumour, CHIMERA will provide both preliminary data and proof-of-principle for larger studies in single tumour sites. CHIMERA is sponsored by the Institute of Cancer Research, LONDON. Funding is also provided by the Institute of Cancer Research.

Studieöversikt

Studietyp

Observationell

Inskrivning (Beräknad)

94

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

      • London, Storbritannien, SW3 6JJ
        • Rekrytering
        • Royal Marsden NHS Foundation Trust
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

N/A

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Patients receiving any type of radiotherapy are eligible for CHIMERA with lung, head and neck, bladder, cervical or rectal cancer

Beskrivning

Inclusion Criteria:

  • Patients receiving any type of radiotherapy are eligible for CHIMERA provided they are at least 18 years of age and can attend routine follow up appointments

Exclusion Criteria:

  • As immunodeficiency due to HIV/AIDS or other infective or autoimmune immunological conditions may impact feasibility and results of immune profiling, immunosuppressed patients due to infection such as HIV, Hepatitis B/C are excluded.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Lung cancer 1

5 patients with peripheral lung tumours and 5 patients with central lung tumours receiving radical radiotherapy without chemotherapy will be recruited.

Tissue and blood sample collection

Lung cancer 2

12 patients. To establish the feasibility of ctDNA profiling before, during and after radiotherapy for non-small cell lung cancer (NSCLC).

Tissue and blood sample collection

Head and Neck cancer

This pilot includes 12 patients (6 HPV+ and 6 HPV-) head and neck cancer patients

Tissue and blood sample collection

Cervical cancer

12 patients to establish the feasibility of tumour TCR-Seq profiling before, during and after radiotherapy for cervix cancer. This includes patients receiving either radiotherapy or chemoradiotherapy

Tissue and blood sample collection

Bladder cancer 1

12 patients to establish the feasibility of collecting urine-derived lymphocytes suitable for flow cytometry before, during and after chemoradiotherapy.

Tissue and blood sample collection

Bladder cancer 2

24 patients To establish the feasibility of tumour TCR-Seq profiling before, during and after chemoradiotherapy for bladder cancer, in comparison to a cystectomy sample.

Tissue and blood sample collection

Rectal cancer 1

12 patients To determine the feasibility of detecting changes in gene expression using multiple tissue samples during chemoradiotherapy treatment for rectal cancer

Tissue and blood sample collection

Rectal cancer 2

12 patients To determine the feasibility of detecting changes in gene expression using multiple tissue samples during radiotherapy treatment for rectal cancer

Tissue and blood sample collection

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The feasibility of measuring the change in immune cell repertoire before, during and after radiotherapy
Tidsram: defined as successful profiling of the immune cell repertoire in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.

establishment of proof-of-principle that immune changes occur during and after radiotherapy. Measurement tool is multiparametric flow cytometry immune panel.

defined as successful profiling of the immune cell repertoire in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The feasibility of evaluation of ctDNA dynamics before, during and after radiotherapy
Tidsram: Feasibility is defined as successfully measurement of ctDNA dynamics in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.

The feasibility of evaluation of ctDNA dynamics before, during and after radiotherapy. Measurement tool is targeted DNA sequencing with reference to baseline tumour.

Feasibility is defined as successfully measurement of ctDNA dynamics in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

20 maj 2022

Primärt slutförande (Beräknad)

30 juni 2028

Avslutad studie (Beräknad)

30 juni 2033

Studieregistreringsdatum

Först inskickad

28 januari 2022

Först inskickad som uppfyllde QC-kriterierna

9 november 2026

Första postat (Faktisk)

16 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 november 2026

Senast verifierad

1 november 2026

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera